Introduction
============

Gastric varices may occur in the cardia or fundus of the stomach in 5--33% of patients with portal hypertension \[[@gou095-B1], [@gou095-B2]\]. Gastric varices are classified into several types: (i) gastric-esophageal varices (GOV)-1 and GOV-2, (ii) concurrent with esophageal varices and isolated gastric varices (IGV)-1 and IGV-2 and (iii) independent from esophageal varices \[[@gou095-B2]\]. Gastric variceal bleeds are rare, but tend to be severe when they occur and are thus associated with high mortality \[[@gou095-B3]\].

Gastric varices are managed by the use of cyanoacrylate injections or transjugular intrahepatic portosystemic shunt (TIPS). Although cyanoacrylate injection is not approved for use in the United States, it is widely used in other countries and a number of studies have demonstrated it to be safe and effective \[[@gou095-B6]\]. Some have recommended it be the first-line therapy for gastric variceal bleeding \[[@gou095-B9]\]. It has also been shown to be more effective than alcohol injection or band ligation \[10, [@gou095-B11]\]. An international consensus meeting in 2005 found glue to be the only agent that should be recommended for controlling fundic gastric varices \[[@gou095-B12]\].

Another frequently employed treatment option is the insertion of a TIPS, which has been proven to be a safe and effective means of relieving portal hypertension, with a success rate as high as 100% \[[@gou095-B13], [@gou095-B14]\]. Uncontrolled trials have suggested that TIPS is an effective treatment for gastric varices in patients who failed to respond to initial endoscopic therapy \[[@gou095-B15], [@gou095-B16]\]. While both TIPS and cyanoacrylate have been proven effective in the treatment of gastric varices, there have been a number of conflicting reports on which is more effective \[[@gou095-B17]\].

The current American Association for the Study of Liver Disease (AASLD) recommendation for treating bleeding gastric fundal varices is to use endoscopic variceal obturation with tissue adhesives, such as cyanoacrylate, as first line and consider TIPS if cyanoacrylate is unavailable or if the bleeding cannot be controlled or recurs despite combined pharmacological and endoscopic therapy \[[@gou095-B1]\]. However, the AASLD cautions that these recommendations are based on relatively few studies.

The aim of our study was therefore to compare short-term treatment outcomes, including re-bleeding and survival, in patients with bleeding gastric varices treated with TIPS or endoscopic N-butyl-2-cyanoacrylate.

Patients and Methods
====================

Patient selection
-----------------

The study was designed as a retrospective cohort analysis. Approval was granted by the Cleveland Clinic Institutional Review Board (IRB). Data was gathered using electronic medical records between 2001 and 2011 that were part of an established IRB-approved database of all patients having undergone TIPS at our institution. A separate database of electronic medical records between 2001 and 2011, of all patients receiving treatment with cyanoacrylate at our institution was also utilized. Data was collected on patient demographics, clinical findings, procedural information, and treatment outcomes.

Patients were included if they had gastric varices as the source of bleeding on upper endoscopy and underwent treatment with either glue or TIPS. This was determined using International Classification of Diseases 9^th^ Revision (ICD-9) procedure codes. Patients were excluded if they had gastric varices but did not receive any therapy. Patients were excluded from the portion of the analysis assessing in-hospital death if they died at an unknown time. Patients meeting the inclusion criteria were divided into two groups: group A, which underwent treatment with TIPS, and group B, which underwent treatment with cyanoacrylate.

Procedures
----------

All TIPS were performed by experienced, fellowship-trained interventional radiologists. TIPS performed at our institution after 2004 made use of covered stents. Injection of cyanoacrylate was performed by advanced therapeutic endoscopists. In all cases, N-butyl-2-cyanoacrylate glue (Histoacryl, B Braun, Germany) was used. All gastric varices treated at our center with cyanoacrylate were GOV-2 based on Sarin's classification system \[[@gou095-B2]\]. It is routine protocol to inject 2 mL of glue into the gastric varices. In patients who had endoscopic control of bleeding, endoscopic sessions were repeated with in 2-3 weeks for repeat treatment until complete obliteration of gastric varices was achieved.

Data collection
---------------

Data was collected on demographic and clinical variables including age, gender, race, alcohol use, tobacco use, etiology of cirrhosis/portal hypertension, infection with hepatitis B or hepatitis C, use of proton pump inhibitors (PPIs), use of octreotide, use of antibiotics, and etiology of gastric varices. We also noted the use of other endoscopic therapies, whether or not hemostasis (immediate cessation of bleeding) was achieved, presence of concurrent esophageal varices, arteriovenous malformations, bleeding, spontaneous bacterial peritonitis (SBP), hepatic venous pressure gradient (HVPG), fresh frozen plasma, need for platelet transfusions, the need for blood transfusions, and the indication for TIPS.

Laboratory data was collected including albumin, bilirubin, blood urea nitrogen, serum creatinine, hemoglobin, platelets, international normalized ratio (INR), partial thromboplastin time (PTT), presence and severity of ascites, presence and grade of encephalopathy, model for end-stage liver disease (MELD) score, Child-Turcotte-Pugh (CTP) score and Child-Pugh class (A, B, or C).

Clinical outcomes
-----------------

Our primary outcomes of interest were short-term treatment outcomes, including re-bleeding within 30 days, re-bleeding in the hospital, need for airway intubation, length of stay in the hospital, acute kidney injury (AKI) following the procedure, in-hospital mortality, and days from procedure until death. We also examined whether or not patients had a repeat esophago-gastroduodenoscopy (EGD) and the indication for the same. Our secondary outcome of interest was to assess in-hospital mortality, particularly disease factors associated with in-hospital death.

Statistical analysis
--------------------

A univariate analysis was performed to compare the two treatment modalities; analysis of variance (ANOVA) or the non-parametric Kruskal-Wallis tests were used for continuous or ordinal variables and Pearson's chi-squared test or Fisher's exact test were used for categorical factors.

In addition, survival analysis was performed to assess in-hospital mortality. Follow-up time was defined as number of days from procedure to either death or discharge. Kaplan-Meier plots with log-rank tests were constructed and univariate Cox regression analysis was performed to assess factors associated with in-hospital mortality. Since only 14 deaths were observed in hospital, no multivariable analysis was done.

A value of *P\<*0.05 was considered statistically significant. SAS (version 9.2, The SAS Institute, Cary, NC, USA) was used to perform all analyses. Data are presented as mean ± standard deviation, median \[P25, P75\] or No. (%).

Results
=======

Characteristics of the study population
---------------------------------------

A total of 169 patients was included in the analysis. The TIPS arm contained 140 patients while the cyanoacrylate arm contained 29 ([Figure 1](#gou095-F1){ref-type="fig"}). Seven patients were excluded as they did not undergo any therapy; in these cases the gastric varices visualized were judged too small to treat. Figure 1.Algorithm of case selection

Patient demographics are summarized in [Table 1](#gou095-T1){ref-type="table"}. Average age was 56 ± 12 years and 62% were male. There were no statistically significant differences between the two groups. Disease factors are presented in [Table 2](#gou095-T2){ref-type="table"}. The most common liver disease etiology was hepatitis (31.0%) followed by alcoholic liver disease (21.9%), cryptogenic disease (14.8%), and non-alcoholic steatohepatitis (NASH) (13.5%). There were no significant differences between the cyanoacrylate arm and the TIPS arm in MELD scores (14.5 ± 9.2 *vs*.** 13.4 ± 6.4; *P* = 0.43), CTP scores (8.0 ± 2.6 *vs*.** 7.8 ± 2.0; *P* = 0.68), or Child-Pugh classes (*P* = 0.74). The only disease factor significantly different between the two groups was disease etiology, with subjects who underwent TIPS more likely to have alcoholic liver disease (24.6% *vs*.** 8.0%) or cryptogenic disease (16.9% *vs*.** 4.0%; *P\<*0.001). Table 1.Patients\' demographics and personal historyFactorTotal (*n* = 169)EGD only (*n* = 29)EGD + TIPS (*n* = 140)*P*-value*n*Summary*n*SummaryAge (years)56.3 ± 12.02956.9 ± 12.014056.2 ± 12.00.75[^a^](#gou095-TF1){ref-type="table-fn"}Male105 (62.1)2915 (51.7)14090 (64.3)0.20[^b^](#gou095-TF2){ref-type="table-fn"}Race291400.35[^b^](#gou095-TF2){ref-type="table-fn"}    Caucasian142 (84.0)23 (79.3)119 (85.0)    African-American16 (9.5)3 (10.3)13 (9.3)    Hispanic3 (1.8)0 (0.0)3 (2.1)    Other8 (4.7)3 (10.3)5 (3.6)Alcohol68 (47.6)2815 (53.6)11553 (46.1)0.48[^b^](#gou095-TF2){ref-type="table-fn"}Smoking96 (65.8)2821 (75.0)11875 (63.6)0.25[^b^](#gou095-TF2){ref-type="table-fn"}HIV1 (1.1)91 (11.1)790 (0.0)0.10[^c^](#gou095-TF3){ref-type="table-fn"}Hepatitis B virus20 (15.4)185 (27.8)11215 (13.4)0.12[^b^](#gou095-TF2){ref-type="table-fn"}Hepatitis C virus45 (33.3)176 (35.3)11839 (33.1)0.85[^b^](#gou095-TF2){ref-type="table-fn"}Prior PPIs74 (53.6)2918 (62.1)10956 (51.4)0.30[^b^](#gou095-TF2){ref-type="table-fn"}PPIs during EGD87 (61.7)2921 (72.4)11266 (58.9)0.18[^b^](#gou095-TF2){ref-type="table-fn"}Octreotide81 (55.1)2917 (58.6)11864 (54.2)0.67[^b^](#gou095-TF2){ref-type="table-fn"}Antibiotics76 (51.7)2918 (62.1)11858 (49.2)0.21[^b^](#gou095-TF2){ref-type="table-fn"}[^1][^2][^3][^4][^5] Table 2.Disease factorsFactorTotal (*n* = 169)EGD only (*n* = 29)EGD + TIPS (*n* = 140)*P*-value*n*Summary*n*SummaryEtiology25130**\<0.001**[**^c^**](#gou095-TF6){ref-type="table-fn"}    Hepatitis48 (31.0)7 (28.0)41 (31.5)    Alcoholic liver disease34 (21.9)2 (8.0)32 (24.6)    Cryptogenic disease23 (14.8)1 (4.0)22 (16.9)    Non-alcoholic steatohepatitis21 (13.5)5 (20.0)16 (12.3)    Primary sclerosing cholangitis8 (5.2)0 (0.0)8 (6.2)    Primary biliary cirrhosis6 (3.9)1 (4.0)5 (3.8)    Others15 (9.7)9 (36.0)6 (4.6)Ascites291330.26[^b^](#gou095-TF5){ref-type="table-fn"}    None89 (54.9)19 (65.5)70 (52.6)    Mild25 (15.4)3 (10.3)22 (16.5)    Moderate/Severe48 (29.6)7 (24.1)41 (30.8)Encephalopathy291320.53[^b^](#gou095-TF5){ref-type="table-fn"}    None134 (83.2)23 (79.3)111 (84.1)    Grade 1--223 (14.3)5 (17.2)18 (13.6)    Grade 3--44 (2.5)1 (3.4)3 (2.3)MELD score13.6 ± 7.02814.5 ± 9.212813.4 ± 6.40.43[^a^](#gou095-TF4){ref-type="table-fn"}CTP score7.8 ± 2.1288.0 ± 2.61257.8 ± 2.00.68[^a^](#gou095-TF4){ref-type="table-fn"}Child-Pugh class281250.74[^b^](#gou095-TF5){ref-type="table-fn"}    A48 (31.4)11 (39.3)37 (29.6)    B74 (48.4)10 (35.7)64 (51.2)    C31 (20.3)7 (25.0)24 (19.2)[^6][^7][^8][^9][^10]

Treatment details
-----------------

[Table 3](#gou095-T3){ref-type="table"} presents a summary of EGD outcomes and details by treatment group. Twenty-nine of the 140 patients who underwent TIPS also underwent treatment with various EGD therapies; seven patients received sclerotherapy, four received epinephrine, two received glue, eight received banding, four received clips, and four underwent balloon-occluded retrograde transvenous obliteration. Hemostatis was achieved in 100% of those who received glue, as opposed to 59.1% of those who underwent TIPS (*P* = 0.031) Table 3.EGD findingsFactorTotal (*n* = 169)EGD only (*n* = 29)EGD + TIPS (*n* = 140)*P*-value*n*Summary*n*SummaryTherapy29139    Sclerotherapy7 (4.2)0 (0.0)7 (5.0)0.22[^c^](#gou095-TF9){ref-type="table-fn"}    Epinephrine4 (2.4)0 (0.0)4 (2.9)0.99[^c^](#gou095-TF9){ref-type="table-fn"}    Glue31 (18.5)29 (100.0)2 (1.4)**\<0.001**[**^b^**](#gou095-TF8){ref-type="table-fn"}    Banding8 (4.8)0 (0.0)8 (5.8)0.19[^c^](#gou095-TF9){ref-type="table-fn"}    Clips4 (2.4)0 (0.0)4 (2.9)0.99[^c^](#gou095-TF9){ref-type="table-fn"}    Balloon4 (2.4)0 (0.0)4 (2.9)0.99[^c^](#gou095-TF9){ref-type="table-fn"}Number of EGD therapies29139**\<0.001**[**^a^**](#gou095-TF7){ref-type="table-fn"}    0116 (69.0)0 (0.0)116 (83.5)    146 (27.4)29 (100.0)17 (12.2)    26 (3.6)0 (0.0)6 (4.3)Hemostasis21 (70.0)88 (100.0)2213 (59.1)**0.031**[**^c^**](#gou095-TF9){ref-type="table-fn"}Esophageal varices117 (69.2)2917 (58.6)140100 (71.4)0.17bArteriovenous malformations1 (0.59)290 (0.0)1401 (0.71)0.99cBleeding26 (15.5)295 (17.2)13921 (15.1)0.77bSBP5 (3.1)292 (6.9)1343 (2.2)0.22cHVPG16 \[[@gou095-B11], [@gou095-B21]\]112 \[[@gou095-B12], [@gou095-B12]\]9516 \[[@gou095-B11], [@gou095-B21]\]0.48aFresh frozen plasma28 (19.0)286 (21.4)11922 (18.5)0.72bPlatelets transfusion17 (11.6)282 (7.1)11915 (12.6)0.42[^b^](#gou095-TF8){ref-type="table-fn"}Blood transfusion81 (53.6)2814 (50.0)12367 (54.5)0.67[^b^](#gou095-TF8){ref-type="table-fn"}[^11][^12][^13][^14][^15][^16]

Treatment outcomes
------------------

For treatment outcomes, the primary endpoint of this study, there were no significant differences between the two groups ([Table 4](#gou095-T4){ref-type="table"}). Re-bleeding rates were 10.3% within the hospital stay and 17.2% within 30 days in the cyanoacrylate arm and 13.8% and 17.4% in the TIPS arm (*P* = 0.62 and *P* = 0.98, respectively). Median length of stay was 6.0 days in the cyanoacrylate arm and 4.5 days in the TIPS arm (*P* = 0.35). We detected no significant differences in immediate post-procedural complications, including the need for intubation (*P* = 0.18), AKI (*P* = 0.14), or encephalopathy (*P* = 0.53). A large number of patients in both groups (55.0%) underwent repeat EGDs for follow-up (60.2%), re-bleeding (32.3%), and surveillance (7.5%); there were no significant differences in receiving repeat EGD (*P* = 0.21) or its indication (*P* = 0.17). Table 4.Treatment outcomesFactorTotal (*n* = 169)EGD only (*n* = 29)EGD + TIPS (*n* = 140)*P*-value*n*Summary*n*SummaryRe-bleed in 30 days29 (17.4)295 (17.2)13824 (17.4)0.98[^b^](#gou095-TF11){ref-type="table-fn"}Re-bleed in hospital22 (13.2)293 (10.3)13819 (13.8)0.62[^b^](#gou095-TF11){ref-type="table-fn"}Intubation39 (24.7)2910 (34.5)12929 (22.5)0.18[^b^](#gou095-TF11){ref-type="table-fn"}Encephalopathy291320.53[^a^](#gou095-TF10){ref-type="table-fn"}    None134 (83.2)23 (79.3)111 (84.1)    Grade 1--223 (14.3)5 (17.2)18 (13.6)    Grade 3--44 (2.5)1 (3.4)3 (2.3)Acute kidney injury25 (15.2)297 (24.1)13618 (13.2)0.14[^b^](#gou095-TF11){ref-type="table-fn"}Repeat EGD93 (55.0)2919 (65.5)14074 (52.9)0.21[^b^](#gou095-TF11){ref-type="table-fn"}Indication19740.17[^b^](#gou095-TF11){ref-type="table-fn"}    Follow-up EGD56 (60.2)15 (78.9)41 (55.4)    Re-bleed/Hemetemesis30 (32.3)3 (15.8)27 (36.5)    Surveillance7 (7.5)1 (5.3)6 (8.1)Length of stay (days)5 \[0, [@gou095-B10]\]296 \[[@gou095-B3], [@gou095-B9]\]1384.5 \[0, [@gou095-B10]\]0.35[^a^](#gou095-TF10){ref-type="table-fn"}In-hospital mortality14 (9.4)273 (11.1)12211 (9.0)0.74[^b^](#gou095-TF11){ref-type="table-fn"}[^17][^18][^19][^20][^21]

Our secondary endpoints of mortality assessment included 149 patients: 20 who died at an unknown time were excluded from this part of the analysis. Fourteen patients died while in the hospital prior to being discharged and 135 were discharged home at 30 days. [Table 5](#gou095-T5){ref-type="table"} presents disease factors associated with in-hospital mortality. [Table 6](#gou095-T6){ref-type="table"} compares EGD findings and short-term outcomes between those who were discharged alive and those who died within the hospital. Significant associations were seen with increased bleeding (HR 4.2; *P* = 0.008) and increased HVPG (HR 1.10; *P* = 0.033) in those who died in the hospital. Those who died in the hospital were more likely to undergo intubation (HR 6.8; *P* = 0.014) and experience AKI (HR 8.2; *P* = 0.002). Table 5.In-hospital death and disease factorsFactorDischarged alive (*n* = 135)In-hospital death (*n* = 14)Hazard Ratio (95% CI)*P*-valuenSummarynSummaryEtiology12214    Hepatitis35 (28.7)7 (50.0)Reference    Alcoholic liver disease26 (21.3)3 (21.4)0.34 (0.08, 1.4)0.13    Cryptogenic disease18 (14.8)2 (14.3)0.46 (0.09, 2.3)0.33    NASH17 (13.9)1 (7.1)0.16 (0.02, 1.3)0.09    Others8 (6.6)0 (0.0)0.16 (0.02, 1.3)0.091Albumin1293.1 ± 0.7142.2 ± 0.80.34 (0.14,0.81)**0.015**Bilirubin1291.4 \[0.9, 2.6\]1411.0 \[4.2, 17.3\]1.07 (1.02, 1.1)**0.007**Blood urea nitrogen13116 \[11, 26\]1434 \[27, 60\]1.02 (1.01, 1.03)**\<0.001**Serum creatinine1310.86 \[0.70, 1.2\]141.5 \[1.2, 2.9\]1.6 (1.2, 2.3)**0.004**Hemoglobin13410.3 ± 2.3148.5 ± 2.10.75 (0.55, 1.02)0.064Platelets13084.5 \[57, 142\]1464.5 \[37, 92\]0.99 (0.98, 1.00)0.13INR1321.2 ± 0.24142.0 ± 0.843.7 (2.1, 6.5)**\<0.001**Partial thromboplastin time12130.9 \[27.5, 34.7\]1443.3 \[34.4, 63.6\]1.2 (1.04, 1.3)^a^**0.009**Ascites132120.93 (0.49, 1.8)0.83    None74 (56.1)5 (41.7)    Mild20 (15.2)1 (8.3)    Moderate/severe38 (28.8)6 (50.0)Encephalopathy131112.1 (0.99,4.6)0.052    None114 (87.0)4 (36.4)    Grade 1--214 (10.7)6 (54.5)    Grade 3--43 (2.3)1 (9.1)MELD score12412.0 ± 5.11427.0 ± 9.01.1 (1.08, 1.2)**\<0.001**CTP score1247.5 ± 1.91111.0 ± 1.81.5 (1.1, 2.0)**0.005**Child-Pugh class124114.0 (1.2, 13.4)**0.025**    A46 (37.1)0 (0.0)    B59 (47.6)3 (27.3)    C19 (15.3)8 (72.7)[^22][^23][^24][^25] Table 6.In-hospital death and EGD findings and treatment outcomesFactorDischarged alive (*n* = 135)In-hospital death (*n* = 14)Hazard Ratio (95% CI)*P*-value*n*Summary*n*SummaryTreatment135140.96 (0.27, 3.4)0.95    EGD only24 (17.8)3 (21.4)    EGD + TIPS111 (82.2)11 (78.6)Sclerotherapy1346 (4.5)141 (7.1)0.78 (0.10, 6.0)0.82Glue13425 (18.7)144 (28.6)1.3 (0.40, 4.1)0.67Banding1347 (5.2)141 (7.1)2.1 (0.26, 16.3)0.49Number of EGD therapies134141.3 (0.62, 2.9)0.45    092 (68.7)6 (42.9)    137 (27.6)7 (50.0)    25 (3.7)1 (7.1)Hemostasis2117 (81.0)84 (50.0)0.34 (0.08, 1.4)0.13Esophageal varices13594 (69.6)149 (64.3)0.79 (0.26, 2.4)0.67Bleeding13417 (12.7)148 (57.1)4.2 (1.5, 12.3)**0.008**SBP1312 (1.5)133 (23.1)3.6 (0.95, 13.7)0.059HVPG7415 \[[@gou095-B11], [@gou095-B21]\]819.5 \[14, 23.5\]1.10 (1.01, 1.2)**0.033**Fresh frozen plasma12221 (17.2)85 (62.5)2.5 (0.56, 11.3)0.23Platelets transfusion12212 (9.8)84 (50.0)3.3 (0.80, 13.6)0.099Blood transfusion12161 (50.4)118 (72.7)0.68 (0.17, 2.7)0.59Re-bleed in 30 days13322 (16.5)145 (35.7)1.3 (0.44, 4.1)0.6Re-bleed in hospital13316 (12.0)145 (35.7)1.5 (0.50, 4.7)0.45Intubation12626 (20.6)1210 (83.3)6.8 (1.5, 31.7)**0.014**Acute kidney injury13213 (9.8)1310 (76.9)8.2 (2.2, 31.1)**0.002**Length of stay (days)1344 \[0, [@gou095-B9]\]147.5 \[[@gou095-B4], [@gou095-B18]\]0.87 (0.75, 1.00)0.055[^26][^27][^28]

Discussion
==========

Gastric varices, though rare, are associated with high mortality \[[@gou095-B3]\]. It has been suggested that the incidence may be increasing, possibly as a secondary effect of banding esophageal varices \[[@gou095-B21]\]; therefore determining the most effective means of treatment---insertion of a TIPS or injection with cyanoacrylates---has received considerable attention.

Our study, with 169 patients, is the largest to date on the comparative effectiveness of glue injection *vs*.** TIPS. The disease burden was not significantly different between the two groups; MELD scores in particular were equivalent. We found no differences in re-bleeding rates, survival, lengths of hospital stay, or post-procedural complications. As there were no significant differences in demographics or disease severity between the two groups, our findings suggest that there is no difference in treatment outcomes between TIPS and treatment with cyanoacrylate.

To date, the only randomized, controlled trial comparing TIPS and cyanoacrylate concluded TIPS to be more effective, based on a lower rate of re-bleeding from gastric varices (11% *vs*.** 38%; *P* = 0.014) \[[@gou095-B17]\]. Overall survival and rates of complications were similar in both groups. Retrospective cohort studies have found that those who underwent treatment with glue had a shorter hospital course (13 days *vs*.** 18 days; *P* = 0.05) \[[@gou095-B19]\], and that patients treated with cyanoacrylate had similar re-bleeding and survival rates, as well as less procedure-related morbidity \[[@gou095-B18], [@gou095-B20]\]. In addition, 41% of patients with a TIPS required re-hospitalization, against 1.6% of patients who were treated with glue (*P\<*0.0001) \[[@gou095-B18]\]. All previous studies agree that the choice of glue or TIPS does not seem to influence overall survival.

Our study agrees with the results of previous retrospective studies---that treatment with TIPS or cyanoacrylate results in equivalent rates of acute complication and survival. We did not detect the shorter hospital stay in the cyanoacrylate arm, found by previous studies \[[@gou095-B22]\]. The median length of stay in both groups was also much shorter in our study (5 days for both groups). We did not observe any significant difference in re-bleeding rates between the two groups, whereas Lo *et al*.** \[[@gou095-B17]\] found that those treated with glue were more likely to have re-bleeding. One possible explanation for the difference in outcomes is that, in their study, 17 out of 37 patients in the cyanoacrylate arm had GOV1-type varices, whereas all of our patients treated with cyanoacrylate had GOV2-type. In addition, liver disease etiology differed between their population and ours. In their population, disease etiology was 78% hepatitis, 16% alcoholic, and 6% cryptogenic whereas, in ours, etiology was 31.0% hepatitis, 21.9% alcoholic, 14.8% cryptogenic, and 13.5% NASH. This suggests that our results may be more applicable to a North American population. Our study agrees with earlier studies, that the choice of glue or TIPS does not seem to affect overall survival; we found in-hospital mortality and overall mortality to be high in both of our study groups.

This study is limited by its retrospective nature and the use of databases, which may have introduced confounds such as incorrect coding. Furthermore this is a single-institutional study, which limits the general applicability of our findings. In addition, not all of the relevant data we wished to collect was recorded in the medical records. It has also been suggested that the type of gastric varices is also an important consideration, as GOV1 may be considered closer to esophageal varices and therefore easier to control with sclerotherapy \[[@gou095-B4]\]. Information on the incidence of bacteremia was also not available. In addition, it has been suggested that TIPS should always be paired with embolization of gastric varices \[[@gou095-B14], [@gou095-B23]\], however, this was not always done in our study population. The results of our study suggest that it may be useful to carry out a randomized, controlled trial across multiple North American institutions, comparing treatment of GOV2-type varices with covered TIPS paired with embolization against endoscopic cyanoacrylate therapy.

Conclusion
----------

Whether TIPS or EGD is superior in managing gastric varices remains a subject of much debate. However, our results suggest that patients with equivalent disease did equally well with either treatment. Therefore, with two equally effective treatment options, the ordering provider may decide which treatment is most appropriate based on several factors, including the availability of TIPS insertion by experienced interventional radiologists or the availability of cyanoacrylate by advanced endoscopists. For patients with hepatic encephalopathy where TIPS may be contraindicated, cyanoacrylate offers an alternative treatment. Finally, with current increased focus on efficient health-care spending, the higher cost of TIPS should be considered in the light of similar outcomes from both treatments.
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[^15]: EGD = esophago-gastroduodenoscopy; HVPG = hepatic venous pressure gradient;

[^16]: SBP = spontaneous bacterial peritonitis; TIPS = transjugular intrahepatic portosystemic shunt.

[^17]: Values presented as Median \[P25, P75\] or *n* (%).

[^18]: ^a^Kruskal-Wallis test

[^19]: ^b^Pearson's chi-squared test

[^20]: ^c^Fisher's exact test.

[^21]: EGD = esophago-gastroduodenoscopy; TIPS = transjugular intrahepatic portosystemic shunt

[^22]: Values presented as mean ± SD, median \[P25, P75\] or *n* (%).

[^23]: Hazard ratios and *P*-values correspond to univariate Cox regression analysis.

[^24]: CTP = Child-Turcotte-Pugh; INR = international normalized ratio; MELD = model for end-stage liver disease; NASH = non-alcoholic steatohepatitis;

[^25]: ^a^HR corresponds to a 10-unit increase in partial thromboplastin time.

[^26]: Values presented as median \[P25, P75\] or *n* (%)

[^27]: Hazard ratios and *P*-values correspond to univariate Cox regression analysis.

[^28]: EGD = esophago-gastroduodenoscopy; HVPG = hepatic venous pressure gradient; SBP = spontaneous bacterial peritonitis; TIPS = transjugular intrahepatic portosystemic shunt
